In this role, he will be responsible for overseeing operational functions key to maximizing the company's organizational efficiency and advancing its pipeline of products.
Ledell joins Aveo from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as chief operating officer and led key business operations during the recent US Food and Drug Administration approval of Rethymic.
Prior to Enzyvant, Ledell served as the chief operating officer at Compass Therapeutics and Horizon Discovery Group.
He was responsible for leading operations at both organizations through several changes in scale.
Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc.
Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.
Aveo is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
Aveo currently markets Fotivda (tivozanib) in the US for the treatment of adult patients with relapsed or refractory renal cell carcinoma following two or more prior systemic therapies.
Aveo continues to develop Fotivda in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development.
Aveo is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886